FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
Portfolio Pulse from
The FDA has updated Exelixis (EXEL) regarding the previously scheduled Oncologic Drugs Advisory Committee (ODAC) meeting. The supplemental New Drug Application (sNDA) for cabozantinib, intended for the treatment of pancreatic neuroendocrine tumors, will not be discussed at the ODAC meeting.
January 10, 2025 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Exelixis's sNDA for cabozantinib will not be discussed at the upcoming ODAC meeting, which may delay potential approval for treating pancreatic neuroendocrine tumors.
The decision not to discuss the sNDA at the ODAC meeting could delay the approval process for cabozantinib, potentially impacting Exelixis's market position and revenue expectations. This news is likely to have a negative short-term impact on EXEL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100